Triple-negative breast cancer survivor sees only benefits from immunotherapy clinical trial
Lori Shults didn’t know much about clinical trials when she first came to MD Anderson in May 2017. “I thought they involved some people getting medicine and others just getting sugar pills,” she recalls. “That sounded too risky for me, so I wasn’t interested.”
Fortunately, the Hill Country school teacher soon learned that her understanding of clinical trials was both limited and inaccurate. She also learned that an innovative clinical...